Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen pharma ltd - trifluoperazine hydrochloride - oral tablet - 5mg

Īrija - angļu - HPRA (Health Products Regulatory Authority)

amdipharm limited - tranylcypromine - coated tablet - 10 milligram(s) - monoamine oxidase inhibitors, non-selective; tranylcypromine

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

cst pharma ltd - tranylcypromine sulfate - oral tablet - 10mg

Lielbritānija - angļu - MHRA (Medicines & Healthcare Products Regulatory Agency)

pilsco ltd - tranylcypromine sulfate - oral tablet - 10mg

Dienvidāfrikas Republika - angļu - South African Health Products Regulatory Authority (SAHPRA)

bm_squib -

Austrālija - angļu - Department of Health (Therapeutic Goods Administration)

bristol-myers squibb australia pty ltd - fluphenazine decanoate -

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - fluphenazine decanoate 25 mg/ml (26.88mg added to provide 25mg/ml plus a 7.5% excess.) - injection (depot) - 25 mg/ml - active: fluphenazine decanoate 25 mg/ml (26.88mg added to provide 25mg/ml plus a 7.5% excess.) excipient: benzyl alcohol nitrogen sesame oil - fluphenazine decanoate is indicated in the long-term management of psychotic disorders including schizophrenia, mania and organic brain syndrome. it is of particular value in the treatment of chronic schizophrenia and for patients who are unreliable at taking oral medication. the drug often alleviates such target symptoms as hallucinations, delusions, confusion and withdrawal. it is not only useful in the hospital milieu but is unparalleled, because of its long duration of action in the long-term maintenance therapy of chronically psychotic patients who are amenable to out-patient therapy. fluphenazine decanoate has not been shown to be effective in the management of behavioural complications in patients with mental retardation.

Jaunzēlande - angļu - Medsafe (Medicines Safety Authority)

bristol-myers squibb (nz) limited - fluphenazine decanoate 100 mg/ml - injection (depot) - 100 mg/ml - active: fluphenazine decanoate 100 mg/ml excipient: benzyl alcohol sesame oil - fluphenazine decanoate is indicated in the long-term management of psychotic disorders including schizophrenia, mania and organic brain syndrome. it is of particular value in the treatment of chronic schizophrenia and for patients who are unreliable at taking oral medication. the drug often alleviates such target symptoms as hallucinations, delusions, confusion and withdrawal. it is not only useful in the hospital milieu but is unparalleled, because of its long duration of action in the long-term maintenance therapy of chronically psychotic patients who are amenable to out-patient therapy. fluphenazine decanoate has not been shown to be effective in the management of behavioural complications in patients with mental retardation.

Īrija - angļu - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals uc - fluphenazine decanoate - solution for injection - 25 mg/ml - fluphenazine

Īrija - angļu - HPRA (Health Products Regulatory Authority)

bristol-myers squibb pharmaceuticals uc - fluphenazine decanoate - solution for injection - 100 mg/ml - fluphenazine